TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of Amantadine Hydrochloride for Treatment of Severe Traumatic Brain Injury (TBI)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Individuals between ages 16 and 65 with traumatic brain injury as defined by the TBI Model System syllabus (i.e., damage to brain tissue caused by an external mechanical force as evidenced by loss of consciousness or post-traumatic amnesia due to brain trauma, skull fracture, or objective neurological findings that can be reasonably attributed to TBI on physical or mental status examination).~* Individuals are at least 4 weeks but less than 16 weeks post-injury and have a Disability Rating Scale (DRS) score at enrollment of 12 or greater, and no consistent command following or functional communication (as defined by the JFK.~Exclusion Criteria:~* Women who are pregnant,~* Individuals with missile-type penetrating brain injury,~* Premorbid major CNS/developmental abnormality (e.g., mental retardation, prior significant brain damage, etc.),~* History of more than 1 seizure (clinical or electrographic, but not including epileptiform or other irritative discharges) in the 4 weeks prior to enrollment (individuals with premorbid idiopathic epilepsy are eligible to enroll under two conditions: a) if their pre-injury seizure frequency was less than once/month and they have had no more than 1 seizure/month since injury and b) if a clear provocation was present that would otherwise disqualify a subject, the subject can be enrolled, since these events would not be considered idiopathic),~* Prior exposure to AH post-TBI,~* Unwillingness to discontinue or change confounding psychotropic drugs prior to enrollment, OR~* Allergy or medical contraindication to AH and significant impairment of renal function (as evidenced by a calculated creatinine clearance of \< 60 ml/min).

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Amantadine HCL (Type: EXPERIMENTAL): 100mg BID administered for 2 weeks, then increased to 150mg BID in week 3 if change on primary outcome measure (ie Disability Rating Scale, DRS) was less than 2 points after week 2. If change in DRS score remained less than 2 points after week 3, dose was increased to 200mg BID in week 4.
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Melatonin on Seizure Outcome, Neuronal Damage and Quality of Life in Patients With Generalized Epilepsy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All patients with the clinical diagnosis of generalized epilepsy with generalised onset motor seizure (ILAE 2017) with a history of an episode of seizure within 72 hours of presentation.~* Patients aged 18-60 years, of either sex.~* Treatment-naive patients or patients who had not taken any treatment for at least 4 weeks before inclusion.~Exclusion Criteria:~* History of any recent traumatic brain injury, cerebral ischemia/TIA/stroke.~* Patients with neuroendocrinal tumors.~* History of any invasive neurosurgical/non-invasive neuropsychiatric procedure.~* Patients who are already under treatment for the presenting conditions.~* Medication history of psychoactive or central nervous system depressant drugs.~* Pregnant and nursing women.~* Patients with a history of allergy to valproate, melatonin or other melatonin agonists.~* Patients with drug/alcohol abuse.~* Patients with any hepatic dysfunction.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Control Arm (Type: PLACEBO_COMPARATOR): The patients in Control Arm will receive placebo with valproate (20 mg/kg).
- Melatonin Arm (Type: EXPERIMENTAL): The Experimental Arm will receive tablet melatonin as an add-on to valproate. Melatonin will be prescribed 3 mg/day to the patients and will be advised to take 30 minutes before bedtime.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Casein Phosphopeptide--amorphous Calcium Phosphate on Human Enamel Subjected to in Vivo Acid Attacks

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 to 60 years of age and in good general health~* Dental erosion and wear degree is 0-1~Exclusion Criteria:~* Systemic diseases or oral mucosal disorders~* Current orthodontic treatment~* Pregnancy~* Known allergies to the experimental drink~* Had been given drugs which lead to dry oral more regularly within half a year

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- CPP-ACP (Type: EXPERIMENTAL): Tooth mousse (GC, Japan) application on the specimen surface for 3 min.
- Deionized water (Type: PLACEBO_COMPARATOR): Deionized water application on the specimen surface for 3 min

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage II or Stage III Bladder Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed stage II or III (T2-4a, Nx or N0, M0) primary carcinoma of the bladder with muscle invasion~  * Resectable disease~ * Prostatic urethral involvement with transitional cell carcinoma allowed, if completely resected and no evidence of stromal invasion~ * No tumor-related hydronephrosis~* Positive lymph node must be evaluated by lymphadenectomy or percutaneous needle biopsy~  * No nodal metastases~* No distant metastases~* No more than 6 weeks since prior transurethral resection of the bladder tumor~  * Functioning bladder~PATIENT CHARACTERISTICS:~Age:~* Adult~Performance status:~* Zubrod 0-1~Life expectancy:~* Not specified~Hematopoietic:~* Hemoglobin at least 10 g/dL~* White blood cell (WBC) count of at least 4,000/mm\^3~* Absolute neutrophil count at least 1,800/mm\^3~* Platelet count at least 100,000/mm\^3~Hepatic:~* Bilirubin no greater than 2.0 mg/dL~Renal:~* Creatinine no greater than 1.5 mg/dL~* Creatinine clearance at least 60 mL/min~Other:~* No other prior or concurrent malignancy within the past 5 years except curatively treated nonmelanoma skin cancer, stage I prostate cancer, or carcinoma in situ of the cervix~* Not pregnant~* Negative pregnancy test~* Fertile patients must use effective contraception~* Medically operable~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* Not specified~Chemotherapy:~* No prior systemic chemotherapy~Endocrine therapy:~* Not specified~Radiotherapy:~* No prior pelvic radiotherapy~Surgery:~* See Disease Characteristics~Other:~* No concurrent potential nephrotoxic or ototoxic drugs (e.g., aminoglycosides)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): Transurethral surgery with chemotherapy and radiation therapy followed by either selective bladder preservation or radical cystectomy followed by adjuvant chemotherapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Compare the Effects of Exenatide and Sitagliptin on Postprandial Glucose in Subjects With Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Treatment with metformin for at least 2 months~* Has HbA1c 7.0% to 11.0%, inclusive, at screening~* Body mass index (BMI)25 kg/m\^2 to 45 kg/m\^2, inclusive~* List of medications that are not allowed or the patient has been on stable treatment for at least 2 months:~  * Hormone replacement therapy (female subjects)~ * Oral contraceptives (female subjects)~ * Antihypertensive agents~ * Lipid-lowering agents~ * Thyroid replacement therapy~Exclusion Criteria~* Has been treated with exenatide (BYETTA®) or any DPP-4 inhibitor prior to screening~* Received any study medication or participated in any type of clinical trial within 30 days prior to screening~* Has donated blood within 60 days of screening visit or is planning to donate blood during the study~* Treated with any of the following medications:~  * Sulfonylurea or Thiazolidinedione within 3 months of screening;~ * Alpha-glucosidase inhibitor, meglitinide, nateglinide, or pramlintide (SYMLIN®)within 30 days of screening;~ * Insulin within 2 weeks prior to screening or insulin for longer than 1 week within 6 months of screening;~ * Drugs that directly affect gastrointestinal motility, including but not limited to, anticholinergics, macrolide antibiotics, dopamine antagonists, opioids, and Reglan®(metoclopramide);~ * Systemic corticosteroids by oral, intravenous, or intramuscular route; or potent, inhaled, or intrapulmonary (including ADVAIR®) steroids known to have a high rate of systemic absorption;

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Sequence A (Type: EXPERIMENTAL): None
- Sequence B (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Allogeneic Mesenchymal Bone Marrow Cells in Subjects With Ischemic Stroke

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of ischemic stroke for longer than 6 months~* Brain CT/MRI scan at initial diagnosis and at enrollment consistent with ischemic stroke~* No substantial improvement in neurologic or functional deficits for the 2 months prior to enrollment~* NIHSS score between 6-20~* Life expectancy greater than 12 months~* Prior to treatment patient received standard medical care for the secondary prevention of ischemic stroke~* Adequate organ function as defined by the following criteria:~Exclusion Criteria:~* History of uncontrolled seizure disorder~* History of cancer within the past 5 years.~* History of cerebral neoplasm~* Positive for hepatitis B, C or HIV~* Myocardial infarction withing six months of study entry~* Findings on baseline CT suggestive of subarachnoid or intracerebral hemorrhage within past 12 months.~* Allergies to Bovine or Porcine products

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Stem cells (Type: EXPERIMENTAL): All subjects will receive allogeneic adult mesenchymal bone marrow stem cells

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: BOTOX® for the Treatment of Platysma Prominence

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Female participants willing to minimize the risk of inducing pregnancy for the duration of the clinical study and follow-up period~* A female participant is eligible to participate if she is not pregnant (has a negative urine pregnancy result prior to randomization), not breastfeeding, and at least one of the following conditions applies:~  1. Not a woman of childbearing potential (WOCBP) OR~ 2. A WOCBP who agrees to follow the studies contraceptive guidance during the treatment and follow-up period through study exit.~* Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this study's protocol~Exclusion Criteria:~* Any medical condition that may put the participant at increased medical risk with exposure to BOTOX®, including diagnosed myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis, or any other condition that might interfere with neuromuscular function~* Participant has an anticipated need for treatment with botulinum toxin of any serotype for any indication during the study (other than study intervention)~* Anticipated need for surgery or overnight hospitalization during the study~* Current enrollment in an investigational drug or device study or participation in such a study within 30 days of entry into this study~* Females who are pregnant, nursing, or planning a pregnancy during the study~* Known immunization or hypersensitivity to any botulinum toxin serotype~* History of alcohol or drug abuse within 12 months of the study~* Participant has tattoos, jewelry, or clothing that cannot be removed, and that obscure the neck

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Participants received matching placebo as superficial intramuscular injections administered to the platysma muscle on Day 1.
- BOTOX® Low Dose (Type: EXPERIMENTAL): Participants received BOTOX® Low Dose as superficial intramuscular injections administered to the platysma muscle on Day 1.
- BOTOX® High Dose (Type: ACTIVE_COMPARATOR): Participants received BOTOX® High Dose as superficial intramuscular injections administered to the platysma muscle on Day 1.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pre-Exposure Prophylaxis in YMSM

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Willing and able to independently provide written informed consent;~* Of male gender at birth;~* Between the ages of 18 years and 0 days through 22 years and 364 days at the time of signed informed consent;~* Self-reporting at least one episode of unprotected anal intercourse with a male within the last 12 months at the time of Personal Digital Assistant (PDA) Screening Interview;~* Tests HIV negative at time of screening (using any FDA-approved HIV diagnostic test);~* Willing to provide locator information to study staff;~* Willing to be assigned to any of the three biomedical intervention conditions;~* Does not report intention to relocate out of the study area during the course of the study; and~* Does not have job/other obligations that would require long absences from the area (\> 4 weeks at a time).~Exclusion Criteria:~* Transgender (behavioral intervention not targeted toward this population);~* Presence of serious psychiatric symptoms (e.g., active hallucinations);~* Visibly distraught at the time of consent (e.g., suicidal, homicidal, exhibiting violent behavior);~* Intoxicated or under the influence of alcohol or other drugs at the time of consent;~* Acute or chronic hepatitis B infection (exclude if hepatitis B surface antigen positive);~* Renal dysfunction (Creatinine Clearance \< 75 ml/min); Use Cockcroft-Gault equation: Glomerular Filtration Rate (GFR) = (140-Age in years) x (Weight in kg) / (72 x serum creatinine) for males~* Any history of bone fractures not explained by trauma;~* Confirmed proteinuria (repeated positive \[\> 2+\] urine dipstick), unless explained by orthostatic proteinuria;~* Confirmed glucosuria (repeated positive \[\> 1+\] urine dipstick) in the presence of normal blood glucose (\<120 mg/dL);~* Any Grade 3 toxicity on screening tests/assessments;~* Concurrent participation in an HIV vaccine study or other investigational drug study; or~* Known allergy/sensitivity to the study drug or its components.~* Use of disallowed medications

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 22 Years
- Healthy Volunteers: t

Study Arms:
- FTC/TDF as PrEP (Type: EXPERIMENTAL): Blinded treatment with FTC (Emtricitabine) and TDf (Tenofovir)Pre-Exposure Prophylaxis (PrEP); HIV behavioral intervention
- Placebo Pill Control (Type: PLACEBO_COMPARATOR): Blinded administration of placebo pill; HIV behavioral intervention
- No Pill Control (Type: ACTIVE_COMPARATOR): Subjects receive HIV behavioral intervention but no pill.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy Parecoxib and Ketorolac as Preemptive Analgesia in Spine Fusion

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients undergoing lumbar spinal fusion for one to three levels~* ASA class I or II~Exclusion Criteria:~* History of allergy to Sulfa group~* History of allergy to OPOID or NSAIDs~* Contraindicate to NSAIDs use~* History of coagulopathy or platelet disfunction

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Parecoxib (Type: EXPERIMENTAL): Parecoxib
- Ketorolac (Type: EXPERIMENTAL): Ketorolac
- No medication (Type: NO_INTERVENTION): No medication

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: HORIZON-PFT: Pivotal Fracture Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Female, 65-89 years old~* No history of severe liver, kidney or eye disease~Exclusion Criteria:~* Current bisphosphonate users such as Aredia® (pamidronate), Didronel® (etidronate), Fosamax® (alendronate), Actonel® (risedronate), Skelid® (tiludronate)~* Using hip protectors~Other protocol-defined inclusion/exclusion criteria may apply.

- Gender: FEMALE
- Minimum Age: 65 Years
- Maximum Age: 89 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Acupuncture for Seasonal Allergic Rhinitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Female or male patients (aged 16-45 years) with seasonal allergic rhinitis, clinically positive and test positive (skin-prick test and/or RAST) to grass and birch pollen~* Patients with \>2 years of moderate to severe SAR~* Positive skin-prick test and/or RAST (at least class 2) results~* Visual analogue scale \>40mm and \<80 mm for SAR symptoms during the past year~* Patients must be able to complete a diary for self-evaluation of symptoms and recording use of anti-symptomatic medication~* Use of, or indication for, oral antihistamines as anti-allergic medication~* Written informed consent~Exclusion Criteria:~* Perennial SAR or other types of chronic rhinitis~* Allergic asthma and/or moderate to severe atopic dermatitis~* Active tuberculosis~* Autoimmune disorders~* Severe chronic inflammatory diseases~* History of anaphylactic reactions~* Hypersensitivity to Rescue medication or related drugs used in study related drugs~* Specific immunotherapy \>3 years~* Simultaneous participation in other clinical trials~* Serious acute or chronic organic disease or mental disorder~* Pregnancy or breast feeding~* Allergy desensitisation therapy (current, during the past two years, or planned in the next two years)~* Blood coagulation disorder and/or current use of anticoagulants~* Previous acupuncture treatment for SAR~* Any Complementary and alternative medicine treatment at the moment, in the last three months or planned in the next two years

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): verum acupuncture plus rescue medication (up to 2 doses of second-generation oral antihistamines daily (e.g. 2 x 1 cetirizine dihydrochloride/daily))
- 2 (Type: PLACEBO_COMPARATOR): minimal (sham) acupuncture plus rescue medication (up to 2 doses of second-generation oral antihistamines daily (e.g. 2 x 1 cetirizine dihydrochloride/daily))
- 3 (Type: ACTIVE_COMPARATOR): rescue medication (up to 2 doses of second-generation oral antihistamines daily (e.g. 2 x 1 cetirizine dihydrochloride/daily))alone

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Randomised Controlled Trial of Intubation With the McGrath Series 5 Video Laryngoscope vs the Macintosh Laryngoscope

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults (18 years and over) scheduled for elective surgery whose anaesthetic plan would normally include oral intubation using a Macintosh laryngoscope blade after induction of general anaesthesia and who have given valid informed consent.~Exclusion Criteria:~* Patients requiring special techniques for intubation such as rapid sequence induction~* Adults who have learning difficulties~* Are unconscious or very severely ill~* Have a terminal illness; are in an emergency situation~* Have a mental illness~* Have dementia~* Prisoners~* Those who could be considered to have a particularly dependent relationship with the investigator and other vulnerable groups.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intubation c McGrath videolaryngoscope (Type: ACTIVE_COMPARATOR): Tracheal Intubation using McGrath video-laryngoscope
- Intubation using Macintosh Laryngoscope (Type: ACTIVE_COMPARATOR): Tracheal intubation using Macintosh Laryngoscope

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete